BioMarin pullback a buying opportunity, says JPMorgan JPMorgan attributes yesterday's weakness in shares of BioMarin to very high expectations for BMN 673 and a broader biotech sell-off. The firm believes BMN 673 has shown clear anti-tumor activity and recommends using the dip as a buying opportunity.
Subscribe for More Information
